Af­ter land­ing funds from Roy­al­ty, Cy­to­ki­net­ics an­nounces afi­camten PhII re­sults; Pol­ish CRO Selvi­ta re­struc­tures in search for new growth

Cal­i­for­nia-based Cy­to­ki­net­ics an­nounced that pos­i­tive re­sults from a Phase II tri­al of afi­camten showed pos­i­tive re­sults in pa­tients bat­tling hy­per­trophic car­diomy­opa­thy.

The third co­hort of the RED­WOOD-HCM tri­al showed sub­stan­tial re­duc­tions in the av­er­age left ven­tric­u­lar out­flow tract gra­di­ent in pa­tients whose back­ground in­clud­ed be­ing treat­ed with disopy­ra­mide and a be­ta-adren­er­gic block­er. Each pa­tient re­ceived up to three dos­es dai­ly.

Re­sults showed that there were no in­stances of left ven­tric­u­lar ejec­tion frac­tion be­low 50%. Afi­camten is an in­ves­ti­ga­tion­al car­diac myosin in­hibitor. Treat­ment in the tri­al last­ed 10 weeks, with a 4-week fol­low-up pe­ri­od com­ing in af­ter the last dose. Thir­teen pa­tients were en­rolled, and all of them com­plet­ed the study on treat­ment, Cy­to­ki­net­ics said.

In a state­ment, EVP of R&D Fady Ma­lik said:

These re­sults rep­re­sent the first re­port of pa­tients with ob­struc­tive HCM treat­ed with a com­bi­na­tion of a car­diac myosin in­hibitor and disopy­ra­mide and sup­port our plan to in­clude this pa­tient pop­u­la­tion in SE­QUOIA-HCM, our Phase 3 tri­al, which is im­por­tant giv­en these pa­tients have ex­haust­ed oth­er avail­able med­ical ther­a­pies. We look for­ward to ini­ti­at­ing screen­ing of pa­tients in SE­QUOIA-HCM soon and look for­ward to shar­ing these re­sults from Co­hort 3 with the med­ical com­mu­ni­ty in April.

Ear­li­er this month, Roy­al­ty Phar­ma agreed to lend up to $300 mil­lion to sup­port the com­mer­cial­iza­tion of ome­cam­tiv mecar­bil, Cy­to­ki­net­ics’ lead can­di­date, and the de­vel­op­ment of afi­camten. In re­turn, Roy­al­ty is due a 4.5% roy­al­ty on sales for up to $1 bil­lion, and 3.5% on sales above $1 bil­lion. — Kyle Blanken­ship

Pol­ish CRO plots re­struc­ture, re­ori­ent­ing lead­er­ship team

Pol­ish CRO Selvi­ta is tear­ing down and re­build­ing its busi­ness with plans to com­plete­ly re­jig­ger its lead­er­ship team as it hunts for growth, the small firm said Tues­day.

First, the firm is plan­ning to in­te­grate its “drug dis­cov­ery area, in­te­gra­tion of busi­ness de­vel­op­ment ac­tiv­i­ties, and cre­ation of a de­part­ment sup­port­ing the man­age­ment of op­er­a­tions and in­vest­ments,” ac­cord­ing to a re­lease. That unit will be led by Adri­jana Vin­ter, who was most re­cent­ly a man­ag­ing di­rec­tor at Fi­delta.

Next, the firm will al­so in­te­grate its sales and busi­ness unit. That area will be helmed by Milosz Gru­ca, who will take the CCO role.

Selvi­ta al­so plans to add a new R&D fa­cil­i­ty in Krakow that will even­tu­al­ly hold up to 1,000 re­searchers, the com­pa­ny said. — Josh Sul­li­van

George Scangos (L) and Marianne De Backer

Pi­o­neer­ing biotech icon George Scan­gos hands in his re­tire­ment pa­pers — and this time it’s for re­al

George Scangos, one of the all-time great biotech CEOs, says the time has come to turn over the reins one last time.

The 74-year-old biotech legend spent close to three decades in a CEO post. The first was at Exelixis — which is still heavily focused on a drug Scangos advanced in the clinic. The second “retirement” was at Biogen, where he and his team were credited with a big turnaround with the now fading MS blockbuster Tecfidera. And the third comes at Vir, where he traded in his Big Biotech credentials for a marquee founder’s role back on the West Coast, hammering out a Covid-19 alliance with Hal Barron — then R&D chief at GSK — and breaking new ground on infectious diseases with some high-powered venture players.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jeanne Loring, director of the Center for Regenerative Medicine (Credit: Jamie Scott Lytle)

A stem cell pi­o­neer sent an ex­per­i­ment in­to space. Pa­tients are the next fron­tier

Last July, Jeanne Loring stood on a dirt road surrounded by Florida swampland and watched as a nearby SpaceX rocket blasted into the sky. The payload included a very personal belonging: cell clusters mimicking parts of her brain.

For more than two decades, Loring has been at the forefront of a stem cell field that always seems on the brink of becoming the next thing in medicine, but has been slow to lift off.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

FDA re­ports ini­tial 'no sig­nal' for stroke risk with Pfiz­er boost­ers, launch­es con­comi­tant flu shot study

The FDA hasn’t detected any potential safety signals, including for stroke, in people aged 65 years and older who have received Pfizer’s bivalent Covid booster, one senior official told members of the agency’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Thursday.

The update comes as the FDA and CDC investigate a “preliminary signal” that may indicate an increased risk of ischemic stroke in older Americans who received Pfizer’s updated shot.

FDA cuts off use for As­traZeneca’s Covid-19 ther­a­py Evusheld

The FDA has stopped use of another drug as a result of the new coronavirus variants. On Thursday, the agency announced that AstraZeneca’s antibody combo Evusheld, which was an important prevention option for many immunocompromised people and others, is no longer authorized.

The FDA said it made its decision based on the fact that Evusheld works on fewer than 10% of circulating variants.

Evusheld was initially given emergency authorization at the end of 2021. However, as Omicron emerged, so did studies that showed Evusheld might not work against the dominant Omicron strain. In October, the FDA warned healthcare providers that Evusheld was useless against the Omicron subvariant BA.4.6. It followed that up with another announcement earlier this month that it did not think Evusheld would work against the latest Omicron subvariant XBB.1.5.

Evotec inks li­cense agree­ment with J&J; On­colyt­ic virus biotech prices $15M IPO

Drug discovery and development player Evotec entered another licensing deal with Big Pharma — this time with J&J’s Janssen.

The companies put out word that they entered into a strategic collaboration and license agreement with each other that focuses on targeted immune-based cancer therapies, to be commercialized by Janssen.

According to a statement, the collaboration will hinge on Evotec’s integrated drug discovery and manufacturing capabilities. During the pre-clinical R&D phase, the companies will collaborate closely — and then Janssen will take on full responsibility for both clinical development and commercialization.

In­vestor 'misalign­men­t' leads to tR­NA biotech's shut­ter­ing

A small biotech looking to carve a lane in the tRNA field has folded, an investor and a co-founder confirmed to Endpoints News.

Similar to Flagship’s Alltrna and other upstarts like Takeda-backed hC Bioscience, the now-shuttered Theonys was attempting to go after transfer RNA, seen as a potential Swiss Army knife in the broader RNA therapeutics space. The idea is that one tRNA drug could be used across a galaxy of disorders and diseases.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.

#JPM23: What's re­al­ly dri­ving the cost of health­care and drugs in 2023?

Executive Editor Drew Armstrong spoke with PhRMA CEO Steve Ubl, EmsanaRx CEO Greg Baker and ICER President Steve Pearson about how the debate over drug costs has changed (or not) in the last decade, the shifting payer landscape and why there seems to be so little movement on drug rebates. This transcript has been edited for brevity and clarity.

Drew Armstrong:

So first of all, thank you to everybody for being here and for our panel for being here. Incredibly excited to have this discussion on the cost of healthcare and drugs and what’s driving that. We’re here with Steve Ubl, the head of PhRMA. Thank you so much. Steve Pearson from ICER, and Greg Baker from EmsanaRx. I want to start this conversation with a little bit of a personal reminiscence. So about almost 10 years exactly. I was a reporter back in my previous job and I was covering drug pricing and Gilead had just launched their hepatitis C drug and I was having a conversation with another Steve over at Express Scripts and he made some comments essentially about how they intended to launch a price war over hepatitis C therapies.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pa­tient death spurs tri­al halt for Ma­gen­ta Ther­a­peu­tics

Magenta Therapeutics is pausing an early-stage clinical trial after a patient died. The death was deemed to be possibly related to its drug, MGTA-117.

The biotech said the pause of the Phase I/II trial is voluntary and gives it time to review all available data before deciding what to do next. It’s also reported the known information to the FDA.

The dose-escalation trial was designed to test whether MGTA-117, an antibody-drug conjugate, could serve as a more targeted alternative to high-intensity chemotherapy as a conditioning agent for cancer patients who are set to receive a stem cell transplant. It recruited patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

In a win for Re­gen­eron, No­var­tis' sy­ringe for AMD drug de­clared 'un­patentable'

Regeneron has won a patent case against Swiss pharma giant Novartis over the delivery system for its eye drug Eylea.

The US Patent Trial and Appeal Board ruled that Novartis’ pre-filled syringe for injecting its eye medication Lucentis was “unpatentable” and handed the victory to Regeneron and its AMD drug Eylea.

In the initial complaint in 2020, Novartis alleged to the US International Trade Commission that certain pre-filled syringes for the intravitreal injection, and ultimately Regeneron’s delivery system for Eylea, were infringing on Novartis’ patent. Regeneron filed a petition to review Novartis’ claims in 2021.